Chartwell Investment Partners, LLC Blueprint Medicines Corp Transaction History

Chartwell Investment Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 29, 2020	SELL	$57.09 - $79.27 $934,106 - $1.3 Million	-16,362 Closed	0 $0
Q1 2020 Apr 30, 2020	BUY	$48.11 - $82.22 $209,663 - $358,314	4,358 Added 36.3%	16,362 $957,000
Q4 2019 Jan 29, 2020	SELL	$66.73 - $82.59 $785,478 - $972,166	-11,771 Reduced 49.51%	12,004 $962,000
Q2 2019 Aug 19, 2019	BUY	$73.54 - $97.8 $310,265 - $412,618	4,219 Added 21.57%	23,775 $2.24 Million
Q1 2019 Apr 11, 2019	BUY	$48.7 - $86.6 $952,377 - $1.69 Million	19,556 New	19,556 $1.57 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Chartwell Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Chartwell Investment Partners, LLC with notifications on news.